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Follicular lymphoma (FL) is the second most common 
subtype of adult B-cell non-Hodgkin lymphoma (NHL) in 
Western countries.   Most FL patients have incurable disease 
with a generally indolent course with frequent relapses.   The 
eventual development of resistance to chemotherapy or trans-
formation to diffuse large B-cell lymphoma (tFL to DLBCL) 
will lead to death from disease.   Despite a common underly-
ing genetic abnormality, the clinical course of FL patients is 
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The microenvironment influences the behavior of follicular lymphoma (FL) but the specific roles of the immunomodulatory 
BTLA and TNFRSF14 (HVEM) are unknown.   Therefore, we examined their immunohistochemical expression in the intrafol-
licular, interfollicular and total histological compartments in 106 FL cases (57M/49F; median age 57-years), and in nine 
relapsed-FL with transformation to DLBCL (tFL).   BTLA expression pattern was of follicular T-helper cells (TFH) in the intra-
follicular and of T-cells in the interfollicular compartments.   The mantle zones were BTLA+ in 35.6% of the cases with similar 
distribution of IgD.   TNFRSF14 expression pattern was of neoplastic B lymphocytes (centroblasts) and “tingible body macro-
phages”.   At diagnosis, the averages of total BTLA and TNFRSF14-positive cells were 19.2%±12.4STD (range, 0.6%-58.2%) 
and 46.7 cells/HPF (1-286.5), respectively.   No differences were seen between low-grade vs. high-grade FL but tFL was char-
acterized by low BTLA and high TNFRSF14 expression.   High BTLA correlated with good overall survival (OS) (total-BTLA, 
Hazard Risk=0.479, P=0.022) and with high PD-1 and FOXP3+Tregs.   High TNFRSF14 correlated with poor OS and progres-
sion-free survival (PFS) (total-TNFRSF14, HR=3.9 and 3.2, respectively, P<0.0001), with unfavorable clinical variables and 
higher risk of transformation (OR=5.3).   Multivariate analysis including BTLA, TNFRSF14 and FLIPI showed that 
TNFRSF14 and FLIPI maintained prognostic value for OS and TNFRSF14 for PFS.   In the GSE16131 FL series, high 
TNFRSF14 gene expression correlated with worse prognosis and GSEA showed that NFkB pathway was associated with the 
“High-TNFRSF14/dead-phenotype”.
In conclusion, the BTLA-TNFRSF14 immune modulation pathway seems to play a role in the pathobiology and prognosis of 
FL.
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heterogeneous.   Therefore, it is important to identify the 
high-risk patients who will experience rapid disease 
progression.1-4 
In hematological malignancies the tumor microenviron-
ment plays a critical role in tumorigenesis.5   In the case of 
FL, the intimate relationship between the tumor microenvi-
ronment and the neoplastic cells implies a dynamic cross-talk 
in which tumor cells may give and receive instructions 
through a complex system.5   Several lines of investigations 
have highlighted that FL is an immunologically functional 
disease in which an active interaction between tumor cells 
and the functional composition of the microenvironment 
determines the prognosis and response to treatment.6   Gene 
expression profiling studies revealed that survival after initial 
diagnosis of FL could be predicted by biological differences. 
The “immune-response type 1 signature” included genes 
encoding T-cell markers and macrophages and was associ-
ated with a good prognosis.   In contrast, the “immune-
response type 2 signature” that included genes expressed in 
macrophages and dendritic cells associated with a poor prog-
nosis.7   Immunohistochemical studies were developed to bet-
ter characterize the FL microenvironment and its influence on 
the disease outcome.   Early studies strongly suggested that a 
high frequency of CD68+tumor-associated macrophages 
(TAMs) in FL were associated with a poor prognosis and 
later confirmed that this poor prognosis was due to M2-like 
CD163+TAMs.8,9   Regulatory FOXP3+T lymphyocytes 
(Tregs) account for 5-10% of CD4+T-cells and have immune 
suppressive functions.10   Several studies have shown that a 
high frequency of Tregs in FL is associated with a good prog-
nosis and a reduced risk of transformation.1,11   In addition, 
the architectural pattern of Tregs’  infiltration in FL nodes 
also had an effect: a diffuse pattern was associated with a 
good prognosis but a follicular or perifollicular pattern was 
associated with poor prognosis.11   Programmed cell death 
protein 1 (PD-1, also known as PDCD1 and CD279) is a 
member of the CD28 superfamily of membrane receptors that 
have an important function in the regulation of immune 
responses and in the tolerance to self-antigens as well as to 
tumor cells.12   In our previous study, a high frequency of 
PD-1-positive cells infiltrating the tumor correlated with 
favorable survival in patients with FL, independently of the 
FLIPI; and similar results were obtained by another group.3,13 
Overall, these results suggest that the prognosis of FL 
depends on several immune cell subsets and pathways work-
ing simultaneously rather than being dictated by an individ-
ual immune cell subset.6   A marker related to PD-1 is B- and 
T-lymphocyte attenuator (BTLA) and they are both expressed 
by T follicular helper cells (TFH cells).14   BTLA ligand is 
the Tumor necrosis factor receptor superfamily member 14 
(TNFRSF14, also known as HVEM).15   BTLA and TNFRSF14 
crosstalk regulates inhibition and costimulation of several 
key players of the immune system: BTLA functions as an 
inhibitory receptor in T lymphocytes16 while the ligand 
TNFRSF14 produces proinflammatory signals via activation 
of NF-kappaB17 and it is expressed by antigen presenting 
cells.18   Interestingly, TNFRSF14 aberrations in FL increase 
clinically significant allogeneic T-cell responses19 and in non-
small cell lung cancer TNFRSF14 may contribute to the 
immune escape.20
In this study, we have examined a series of FL patients at 
diagnosis and after transformation to DLBCL to determine 
the role of the BTLA and TNFRSF14 immune checkpoint in 
the progression and outcome of FL.   
MATERIALS AND METHODS
Patients and samples
106 diagnostic biopsies of Western FL patients diagnosed 
in a single institution between 1978 and 2008 were included 
in the study, reviewed and re-classified according to the 
WHO classification.21   The median age of the patients was 
57 years (range, 26-88) and the male/female distribution 
57/49.   The main initial features of the patients are listed in 
Table 1.   FLIPI4 was retrospectively assessed in 98 patients: 
low-risk, 45 cases (45.9%); intermediate-risk, 22 (22.4%); 
and high-risk, 31 (31.6%).
Staging maneuvers were the standard and included 
patient history and physical examination; blood cell counts 
and serum biochemistry, including LDH and B2M levels; 
Variable No (%)
Age≥60 years 47 44.3
Male sex 57 53.8
Histological grade
   Low grade (1,2) 83 78.3
   High grade (3) 23 21.7
Architectural pattern
   Follicular 99 93.4
   Diffuse  7  6.6
B-symptoms 18 17.3
Poor performance status (ECOG≥2) 15 14.4
Bulky disease (≥10cm) 16 15.4
Ann Arbor Stage IV 65 62.5
Bone marrow involvement 64 61.5
High serum LDH (≥450 IU/L) 22 21.8
High serum β2M (≥3mg/L) 37 38.9
FLIPI
   Good prognosis 45 45.9
   Intermediate prognosis 22 22.4
   Poor prognosis 31 31.6
Table 1. Main clinical and histopathologic features of 106 patients 
with FL at diagnosis
ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehy-
drogenase; β2M, β2-microglobulin; FLIPI, Follicular Lymphoma 
International Prognostic Index.
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computerized tomography scan of chest, abdomen, and pel-
vis; as well as unilateral bone marrow biopsy.   Eighty-three 
patients received combination chemotherapy consisting on 44 
CHOP (cyclophosphamide, adriamycin, vincristine and pred-
nisone) or CHOP-like regimens, 18 FCM (fludarabine, cyclo-
phosphamide and mitoxantrone) or RFCM, and 21 RCHOP 
or RCHOP-like.   In 19 patients the treatment was monother-
apy consisting on six with alkylating monotherapy (chloram-
bucil), four with radiotherapy, one with corticoids, and eight 
with watch and waiting (patients ≥65 years with no high 
tumor burden).   Twenty-seven patients had received ritux-
imab.   Post-therapy restaging consisted of the repetition of 
the previously abnormal tests and/or biopsies.
Response to therapy was assessed according to conven-
tional criteria.   Among the 92 patients with assessable 
response, 60 (65.2%) achieved a complete response (CR), 23 
(25%) a partial response (PR), whereas nine (9.8%) failed to 
respond to treatment.   The median follow-up was 8.13 years, 
with a range from 0.02 to 23.02 years.   The 5, 10 and 15-year 
OS was 74.9% (95% confidence interval (CI): 83.3%-
66.5%), 58.3% (95%CI: 68.3%-48.3%), and 51.6% (95%CI, 
62.4%-40.8%), respectively.   Twelve patients (11.8%) expe-
rienced histological transformation during the follow-up.
The study was approved following the institutional guide-
lines of the Ethical Committee of Hospital Clinic, Barcelona. 
Informed consent was provided according to the Declaration 
of Helsinki.
Immunohistochemical procedures and quantitative 
assessment
Whole tissue sections from paraffin embedded samples 
were immunostained using undiluted hybridoma supernatant 
of anti-BTLA murine monoclonal antibody (AM-005, clone 
FLO67B, Monoclonal Antibodies Unit, Spanish National 
Cancer Research Centre, CNIO, Madrid, Spain), anti-
TNFRSF14 (Rabbit polyclonal to TNFRSF14 - Aminoterminal 
end, ab47677, Abcam, Cambridge, UK) and anti-IgD (FLEX 
Anti-IgD, Code IR517/IS517, Dako Diagnosticos, S.A., 
Barcelona, Spain).   Immunohistochemical staining was auto-
matically performed using a Leica BOND-MAX immunos-
tainer according to manufacturer’s instructions (Leica 
Microsystems, L’Hospitalet de Llobregat, Spain).   Eighty-
three and 91 cases previously studied for FOXP3 and PD-1 
(NAT105) were included in this series.   Follicular and 
interfol·licular BTLA-positive cells were quantified using an 
automated scanning microscope and computerized digital 
image analysis system always under pathologist visual super-
vision as previously described (Ariol SL-50, Leica Biosystems, 
Barcelona, Spain).1,3   Briefly, quantification was performed 
using the gensight multistain assay.   Whole tissue sections 
were automatically scanned at 10x followed by directed high 
magnification at 200x.   Color and shape definition parame-
ters were first assessed and then recalibrated among tissue 
samples.   Positive and negative pixels were counted inde-
pendently in the follicular and interfol·licular compartments. 
The follicular compartment included the mantle zone when 
present.   Once the areas of interest were selected the software 
collected the data automatically.   The presence or absence of 
a BTLA-positive mantle zone (which means that all cells in 
the mantle were positive) was annotated as a qualitative vari-
able.   The number of TNFRSF14-positive cells was quanti-
fied as number of positive cells per HPF (400x magnification; 
Olympus BX51, UPlanFI 40x/0.75; Olympus UK Ltd, Essex, 
UK).   The percentage of BTLA and number of TNFRSF14 
positive cells was recorded in the follicular and interfollicular 
compartments and then the total value was calculated.   
Immunofluorescence was performed using biotinylated 
goat anti-mouse and anti-rabbit IgG antibodies (#BA-9200 
and BA-1000, Vector Laboratories, CA, USA), streptavidin, 
Alexa Fluor 488 and 568 conjugates and ProLong™ Gold 
antifade mountant with DAPI (#S11223, S11226 and 
#P36941, Thermo Fisher Scientific K.K., Tokyo, Japan). 
Zeiss LSM700 laser-scanning confocal microscope was used 
with linear unmixing and spectral imaging following the 
manufacurer’s instructions (Zeiss, Tokyo, Japan) with combi-
nation to Imaris microscopy image analysis software 
(Bitplane AG, Zurich, Switzerland).   Human reactive lym-
phoid t issue was used to analyze the expression of 
TNFRSF14 and BTLA with FOXP3 and PD-1 using the dou-
ble or triple immunofluorescence stainings.   In addition, 
relationship of TNFRSF14 with PAX5 (B-cells), CD21 
(FDCs) and MITF (macrophages) was analyzed as well using 
Bond Polymer Refine Red Detection (#DS9390) and Bond 
Polymer Refine DAB Detection (#DS9800).
Lymphoid tissue from peyer’s patches of small intestine 
of control BALB/c mice were studied by flow cytometry to 
quantify the expression frequency of BTLA and TNFRSF14 
against the markers of B220 (CD45R), CD11C and FOXP3 
as described.22   Same antibodies were used for direct immu-
nofluorescence in frozen tissue.
Gene expression analysis
The online SurvExpress tool23 was used to correlate the 
gene expression levels with the patients’ outcome of the pre-
viously published series of Dave et al. that includes 191 FL 
cases.7   Then, the same FL gene expression and clinical fea-
tures datasets were downloaded from the NCBI, Gene 
Expression Omnibus (GEO), series GSE16131, platform 
GPL96 [HG-U133A], Affymetrix human genome U133A 
array), series matrix file.   Gene Set Enrichment Analysis 
(GSEA) was performed following the Broad Institute soft-
ware and their instructions.24,25   To narrow the differences we 
compared the GSEA between 30 cases of high TNFRSF14 
and dead phenotype vs. 30 cases of low TNFRSF14 and alive 
phenotype.   The target pathway to test was the NFkB immune 
inflammatory gene set, M2645, “hinata”, homo sapiens, from 
the Molecular Signatures Database of Broad Institute.
Statistical analysis
The main initial and evolutive variables were analyzed 
for prognostic significance.   BTLA and TNFRSF14-positive-
cells were initially quantified and analyzed as a continuous 
variable and later the best threshold for overall survival was 
found using Cutoff Finder software.26   Comparison of means 
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was performed with independent-samples T Test, and non-
parametric tests (independent samples) to automatically com-
pare distributions across groups when required.   Categorical 
data were compared using crosstabs, chi-square, using 
Fisher’s exact test when necessary.   Binary logistic regres-
sion was performed to calculate the Odds Ratios.   Survival 
analysis was performed using the Kaplan-Meier analysis with 
Log rank test for univariate analysis; and the Cox Regression 
(method:enter) for multivariate analysis and also for univari-
ate to calculate the Hazard Ratio.   The definition of OS and 
progression-free survival (PFS) were the standard.   Statistical 
significance was stated a priori at P<0.05.   The IBM SPSS 
software, build 1.0.0.1174, 64-bit edition was used for statis-
tical analysis (IBM Japan, Tokyo).
RESULTS
Clinical and histological features of the patients at 
diagnosis
The main clinical and histological features of the 106 
patients at diagnosis are detailed in the methods section and 
summarized in Table 1 and Tables 2.1 and 2.2.   The histolog-
ical distribution was low grade (1 and 2) in 83 cases (78.3%), 
and high grade (3) in 23 (21.7%) cases.   The architectural 
pattern was follicular (i.e. nodular, follicular area>75%) in 99 
(93.4%) and predominantly diffuse (follicular area<25%) in 
seven cases (6.6%).   Clinical variables that were associated 
with unfavorable OS were age (>60 years), a high-grade, the 
presence of B-symptoms, ECOG≥2, high LDH, high B2M 
and high-risk FLIPI (P<0.05).   Variables that were associ-
ated with unfavorable PFS were B-symptoms, ECOG≥2, 
high LDH, high B2M and high-risk FLIPI (P<0.05). 
Overall, our patient population was reflective of a commonly 
observed FL population.
Histopathological features of BTLA-positive cells in FL
BTLA-positive-cells were observed either in the germinal 
centers of follicular areas and in the interfollicular compart-
ment following a T-cell pattern distribution.   In reactive ton-
sils, triple immunofluorescence confirmed the colocalization 
of PD-1 and BTLA in the FTH cells located in the germinal 
centers, while FOXP3 was a specific marker for Tregs 
(Figure 1G).   In addition, BTLA was positive in the mantle 
and marginal zone area in 36 (35.6%) of the cases following 
a pattern of the B-cell staining.   The mantle zone was also 
IgD-positive (Figure 1).
The relationship between the percentage of BTLA posi-
tive cells with a T-cell distribution in samples at diagnosis 
and the pathological characteristics of the patients is shown 
in Table 3.1.   The mean proportion of total BTLA in the 101 
diagnostic biopsies was 19.2% (STD 12.4%; range, 0.55-
57.68%).   Overall, the percentiles 25, 50 and 75 were 9.8%, 
18.3% and 25.4%, respectively.   No differences were found 
between low- and high-grade follicular lymphoma neither in 
the total, (intra)follicular nor interfollicular compartments but 
the transformation to DLBCL was characterized by a striking 
decrease in the number of BTLA-positive cells (18.3±10.2 
vs. 22.1±18.2 vs. 1.9±3.5, respectively; FL vs. tFL P=0.000008). 
FL with a diffuse architectural pattern did not had lower lev-
els of BTLA+cells than those with a follicular pattern (P=N.
S) (Table 3.1).
Thirty-six percent of the FL samples had a BTLA-
positive mantle zone.   No correlation was found with the 
grade of FL (low grade vs. high grade) and the architectural 
pattern (nodular vs. diffuse), 39.2% vs. 22.7% and 36.8% vs. 
16.7%, respectively (P= N.S) (Table 3.1).
Variable P value Hazard Ratio
95% C.I. for HR
Lower Upper
Age >60 y. 0.000193 3.213 1.74 5.936
Sex (male) 0.956 0.984 0.547 1.768
High histological grade 0.001 2.907 1.562 5.413
Diffuse architectural pattern 0.387 0.534 0.129 2.209
B-symptoms 0.002 2.855 1.493 5.463
ECOG≥2 0.000016 4.442 2.256 8.744
Bulky disease (≥10cm) 0.305 0.614 0.241 1.56
Ann Arbor Stage IV 0.635 0.866 0.479 1.566
Bone marrow involvement 0.997 1.001 0.551 1.818
High serum LDH (≥450 IU/L) 0.000144 3.321 1.788 6.168
High serum β2M (≥3mg/L) 0.000202 3.39 1.781 6.455
High risk FLIPI 0.000399 2.962 1.624 5.403
Table 2.1. Overall Survival analysis of the clinicopathological vari-
ables in 106 diagnostic cases of FL.
Variable P value Hazard Ratio
95% C.I. for HR
Lower Upper
Age >60 y. 0.085 1.533 0.942 2.493
Sex (male) 0.627 0.887 0.547 1.439
High histological grade 0.095 1.603 0.921 2.792
Diffuse architectural pattern 0.847 0.905 0.329 2.493
B-symptoms 0.016 2.038 1.143 3.633
ECOG≥2 0.001 2.838 1.559 5.167
Bulky disease (≥10cm) 0.73 1.127 0.572 2.219
Ann Arbor Stage IV 0.408 1.236 0.748 2.043
Bone marrow involvement 0.507 1.184 0.719 1.948
High serum LDH (≥450 IU/L) 0.001 2.501 1.455 4.299
High serum β2M (≥3mg/L) 0.003 2.188 1.302 3.675
High risk FLIPI 0.006 2.052 1.228 3.429
Table 2.2. Progression Free Survival analysis of the clinicopatho-
logical variables in 106 diagnostic cases of FL.
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Fig 1. Immunohistochemical expression of BTLA in FL.
A, Low BTLA expression in FL in all compartments. B, High BTLA expression both in the follicular and 
interfollicular compartments. C, Low BTLA expression in the follicular area, with a follicular T helper cell 
(TFH) pattern. D, High follicular BTLA expression (+weak staining of B cells, phenomena often seen in the 
high BTLA expression cases). E.1, BTLA+mantle zone and E.2, same area stained with anti-IgD antibody. F, 
BTLA expression is very low in transformed FL to Diffuse Large B-cell Lymphoma (tFL). G, Double immu-
nofluorescence combined with peroxidase-DAB-based in reactive tonsil staining using confocal microscopy 
with volume rendering between BTLA (HRP-DAB-based IHC, yellow), PD-1 (red) and FOXP3 (green). The 
staining shows that in the germinal centers BTLA is identifying PD-1+follicular T helper cells (FTH). 
Original magnification of Figures A and B is 100X, the rest are 400X (Olympus BX53).
BTLA-positive cells, % Mantle
No (%) Total Follicular compartment Interfollicular compartment No (%)
Histologic grade
   Grade 1-2 79 (78.2) 18.3±10.2 17.0±10.0 20.1±13.2 31 (39.2)
   Grade 3 22 (21.8) 22.1±18.2 18.9±16.2 25.4±23.4 5 (22.7)
   DLBCL 9 1.9±3.5 - - -
Architectural pattern
   Follicular 95 (94.1) 19.6±12.4 17.8±11.6 21.8±16.1 35 (36.8)
   Diffuse 6 (5.9) 11.6±11.1 - - 1 (16.7)
Total 101 (100) 19.2±12.4 17.4±11.6 21.2±15.9 36 (35.6)
Table 3.1. Distribution of BTLA-positive cells in FL at diagnosis
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Histopathological features of TNFSF14-positive cells in 
FL
In reactive tonsil the TNFSF14-positive cells showed a 
characteristic Golgi staining pattern in the cytoplasm.   In the 
follicular area of reactive tonsil PAX5+lymphocytes also 
stained positive for TNFRSF14 and were surrounded by 
CD21+follicular dendritic cells.   Macrophages were also 
MITF+ (Figure 2A).
In FL, TNFRSF14-positive cells had a histological mor-
phology of B-cell centroblasts and the other positive cells 
had a morphology of macrophages, especially at the stage of 
transformation to DLBCL. (Figure 2B-D).
The relationship between the number of TNFSF14-positive 
cells in samples at diagnosis and the pathological characteris-
tics of the patients is shown in Table 3.2.   The mean number 
of total TNFSF14 in the 92 diagnostic biopsies was 46.7 
cells/HPF (STD 57.8; range, 1-286).   Overall, the percentiles 
25, 50 and 75 were 8.0, 33.3 and 60.3, respectively.   No dif-
ferences were found between low- and high-grade follicular 
lymphoma neither in the total, follicular nor interfollicular 
compartments but the transformation to DLBCL was charac-
terized by a striking increase in the number of TNFRSF14-
positive cells (44.4±56.7 vs. 55.7±62.6 vs. 137.9±91.8, 
respectively; FL vs. tFL P=0.002).   FL with a diffuse archi-
tectural pattern was characterized by a 29% less numbers of 
positive cells although it was not statistically significant, only 
a trend (14.3±11.9 vs. 49.4±59.3, P=0.056) (Table 3.2.).
Correlation between BTLA, TNFSF14, FOXP3 and PD-1 
markers in FL
A significant positive correlation was found between fol-
licular BTLA and follicular PD-1 expression (Spearman cor-
relation P=0.019) as well as with follicular FOXP3 expres-
sion (Pearson correlation P=0.002).   In addition, follicular 
PD-1 also positively correlated with follicular FOXP3 
(Pearson correlation P=0.001).   Total BTLA also positively 
correlated with total FOXP3 (Pearson correlation P=0.025). 
Of note, the presence of a BTLA+mantle also positively cor-
related with follicular FOXP3 (P=0.003).   Follicular 
TNFRSF14 did not correlate with follicular PD-1 or follicu-
lar FOXP3.   Total TNFRSF14 did not correlate with total 
FOXP3 as well.   Total TNFRSF14 and total BTLA didn’t 
correlate either as continuous or as ordinal variable.   
In the mice system in peyer’s patches, B220+CD11C+cells, 
present in the mantle/marginal zone also expressed BTLA. 
Interestingly, by flow cytometry FOXP3+Tregs also could 
express BTLA and/or HVEM.   Of note, one must be cau-
tious when comparing mice and human immune system as 
results cannot be directly translated.   Further analysis will be 
required in the future.   
Relationship between the number of BTLA and 
TNFSF14-positive cells, clinical features and outcome
The total numbers of BTLA and TNFRSF14-positive 
cells did not correlate with the outcome when analyzed as a 
continuous variable, but the cohort was divided in two 
categorical subsets based on high and low positive numbers 
(Figures 3-5).
High BTLA expression, either in intrafollicular (≥4.54%) 
or interfollicular (≥8.05%) areas, and total numbers 
(≥8.59%), correlated with a favorable OS (Kaplan-Meier, 
Log Rank P=0.005, P=0.024 and P=0.022, respectively); the 
Hazard Ratio (HR) was 0.382, 0.478 and 0.479, respectively 
(Figure 3).   The 5- and 15-year OS are shown in Table 4.1. 
The presence of a BTLA-positive mantle zone also correlated 
with favorable OS (P=0.039 and HR of 0.468).   BTLA did 
not correlate with the PFS.   High total BTLA inversely cor-
related with the presence of B-symptoms and high serum 
LDH (Table 4.2) (Figure 3).   When we analyzed only the 
cases treated with rituximab (R-CHOP and R-CHOP-like), 
high total BTLA also associated with a good prognosis of the 
patients (OS) (Figure 5).
High TNFRSF14, either follicular (≥44), interfollicular 
(≥32) and total (≥34.9), correlated with a poor OS: Kaplan-
Meier, Log Rank P=0.000142, P=0.000019 and P=0.000021, 
respectively; the HR was 3.393, 3.636 and 3.863, respec-
tively (Figure 4).   The 5- and 15-year OS is shown in Table 
4.1.   TNFRSF14 also correlated with a poor PFS: Kaplan-
Meier, Log Rank P= 0.000034, P=4.407E-08 and P= 0.000004, 
respectively; the HR was 2.911, 4.094 and 3.236, respec-
tively.   The 5- and 15-year OS is present at Table 4.1.   High 
total TNFRSF14 positively correlated with B-symptoms, 
high LDH, high B2M and FLIPI high risk (Table 4.3). 
TNFRSF14 associated to a higher risk of FL transformation 
to DLBCL: total TNFRSF14 (cut-off at 42.1%), odds-ratio 
5.250 (95% C.I. 1.250-22.058), P=0.024.   Of note, BTLA 
expression did not associate to FL transformation.   In the rit-
umixab-treated group, high total TNFRSF14 also associated 
with a poor OS and PFS (Figure 5).
Both total BTLA and total TNFSF14 expression were 
included with the FLIPI in a Cox model to identify which 
one was more important to predict OS.   TNFRSF14 and 
FLIPI retained its prognostic value.   When tested for PFS 
only TNFRSF14 retained prognostic value (Table 5).
Of note, in this series high total FOXP3 (>5%) correlated 
with a favorable OS (P=0.040, HR: 0.476, 95%CI 0.231-
0.983) as well as high follicular PD-1 (>6%, P=0.001, 
HR:0.364, 95%CI 0.195-0.677).   When total BTLA, total 
TNFRSF14, total FOXP3 and follicular PD-1 expression as 
wel l  as  FLIPI  were included in  a  Cox model ,  only 
TNFRSF14 and FLIPI retained prognostic values.
Gene expression analysis
We used the previously published data of gene expression 
of FL from the series of Dave to validate our immunohisto-
chemical finding at RNA levels.   We could not analyze 
BTLA because that gene was not present in the Affymetrix 
chip at that time.   High TNFRSF14 RNA levels were associ-
ated with a poor OS (P=0.004).   Five- and 15-year OS, high 
vs. medium-low risk: 64.3% (95%CI: 76.7%-51.9%) and 
13.4% (26.3%-0.5%) vs. 74.7% (82.7%-66.7%) and 39.4% 
(51.2%-27.6%).   The Hazard Risk was 1.816 (P=0.005, 
95%CI 1.199-2.751) (Figure 6).
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Fig 2. Immunohistochemical expression of TNFRSF14 (HVEM) in FL.
The TNFRSF14 expression was analyzed first in reactive tonsil. A.1, Reactive tonsil, double immunohisto-
chemistry between PAX5 (DAB, brown) and TNFRSF14 (red) shows that neoplastic B lymphocytes (centro-
blasts) are TNFRSF14 positive. A.2, Double immunohistochemistry between CD21 (DAB, brown) and 
TNFRSF14 (red) shows how TNFRSF14+B lymphocytes (mainly centroblasts) are surrounded by a network 
of CD21+follicular dendritic cells (FDC). A.3, MITF+cells with morphology of FCD and macrophage (red 
color, nuclear staining) are surrounded by TNFRSF14+cells. B, Low frequency of TNFRSF14+cells in FL 
(B.1 400X, B2, magnified inset). C.1, High frequency of TNFRSF14+cells (C.2, inset). D.1, transformed FL to 
DLBCL (tFL) with high TNFRSF14 expression (D.2, inset).
TNFRSF14-positive cells, %
No (%) Total Follicular compartment Interfollicular compartment
Histologic grade
   Grade 1-2 73 (79.3) 44.4±56.7 60.8±86.2 27.9±40.9
   Grade 3 19 (20.7) 55.7±62.6 70.3±89.5 41.1±46.4
   DLBCL 9 137.9±91.8 - -
Architectural pattern
   Follicular 85 (92.4) 49.4±59.3 66.5±88.9 32.2±43.4
   Diffuse 7 (7.6) 14.3±11.9 - -
Total 92 (100) 46.7±57.8 62.8±86.5 30.6±42.2
Table 3.2. Distribution of TNFRSF14-positive cells in FL at diagnosis
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Fig 3. Overall survival of BTLA, FOXP3 and PD-1.
High BTLA expression, either follicular, mantle, interfollicular and total correlated with good OS (P<0.05). 
Same results were found for total FOXP3 and follicular PD-1. Of note, BTLA did not correlate with the PFS.
9
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Fig 4. Overall survival and progression free survival of TNFRSF14.
High TNFRSF14 expression associated with poor prognosis in FL either in the follicular, interfollicular and 
total compartments, for both OS and PFS (P<0.001).
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The GSEA analysis of the NFkB pathway showed an 
enrichment on the TNFRSF14 high and dead phenotype (the 
“high risk” group) (Figure 6).   The genes of the core enrich-
ment were CXCL3, CCL20, CXCL2, IL6, CXCL6, TNFAIP2, 
IRF1, NFKBIA, IL8 and IL1B.
DISCUSSION
In this study, we found that the immune checkpoint genes 
of BTLA and TNFRSF14 (also known as HVEM) are differ-
entially expressed by cells of the immune microenvironment 
and by the neoplastic FL B-lymphocytes.   We found that the 
immunohistochemical protein expression correlated with the 
prognosis of the patients with high BTLA expression being 
associated with good prognosis and high TNFRSF14 expres-
sion with poor outcome, as well as with several clinical vari-
ables.   In addition, we also found that FL transformation to 
DLBCL (tTL) was associated with a decrease of BTLA 
expression but an increase of TNFRSF14.
FL is the second most common subtype of non-Hodgkin 
lymphoma.   It is defined as a lymphoma of follicle center B 
cells, and virtually always demonstrates a growth pattern that 
is partially follicular.   Germinal centers (GCs) are the site of 
antibody diversification and affinity maturation and as such 
are vitally important for humoral immunity.27   One of the 
hallmarks of the GC function is the progressive increase of 
affinity antibodies that is the result of the activation-induced 
cytidine deaminase (AID)-driven somatic hypermutation 
(SHM) of the antigen-binding variable regions of immuno-
globulin (Ig) genes.27,28   SHM generates a panel of mutated B 
cells that are then selected, based on their affinity, to prolifer-
ate and differentiate into antibody-secreting plasma cells 
(PCs) and memory B cells.27   A mature GC is divided into 
two compartments with different functions.   The centroblasts 
in the dark zone proliferate in a meshwork of CXCL12-
expressing reticular cells, express CXCR4 and AID, and 
Fig 5. Overall survival and progression free survival of BTLA and TNFRSF14 on the rituximab-treatment 
cases.
The prognostic relevance of BTLA and TNFRSF14 was maintained when we re-analyzed only the rituximab-
treated patients (RCHOP and RCHOP-like).
11
BTLA and TNFRSF14 in FL prognosis
Overall Survival Progression free survival
5-y 95%CI 15-y 95%CI HR P value 5-y 95%CI 15-y 95%CI HR P value
BTLA
Follicular Low 46.7 72.0 21.4 25 47.7 2.3
0.382 0.005
- - - - - -
- 0.098
High 79.7 88.3 71.1 57.9 69.9 45.9 - - - - - -
Interfollicular Low 55 76.8 33.2 33.3 54.9 11.7
0.478 0.024
- - - - - -
- 0.266
High 79.7 88.5 70.9 57.5 70.0 45.0 - - - - - -
Total Low 54.5 75.3 33.7 35.1 55.7 14.5
0.479 0.022
- - - - - -
- 0.182
High 80.4 89.2 71.6 57.6 70.3 44.9 - - - - - -
Mantle Absent 67.7 79.1 56.3 46.1 59.0 33.2
0.468 0.039
- - - - - -
- 0.272
Present 88.1 99.1 77.1 64.4 85.0 43.8 - - - - - -
TNFRSF14
Follicular Low 85.7 95.5 75.9 71.6 84.7 58.5
3.393 0.000142
61 74.7 47.3 48.9 63.4 34.4
2.911 0.000034
High 60.9 75.8 46.0 22.9 38.8 7.0 21.7 34.4 9.0 5.4 14.8 -4.0
Interfollicular Low 85.7 94.3 77.1 61.2 75.5 46.9
3.636 0.000019
58.5 70.7 46.3 42 55.7 28.3
4.094 4.407E-08
High 48.1 66.9 29.3 23.1 40.0 6.2 5.6 15.4 -4.2 0 0.0 0.0
Total Low 90 98.2 81.8 71.5 84.8 58.2
3.863 0.000021
59.4 72.1 46.7 43 57.7 28.3
3.236 0.000004
High 53.9 69.4 38.4 22.7 38.6 6.8 14.5 26.8 2.2 5.5 14.9 -3.9
Table 4.1. Correlation between BTLA and TNFRSF14-positive cells and prognosis
Variable P value Odds Ratio
95% C.I. for OR
Lower Upper
Age >60 y. 0.443 1.465 0.553 3.884
Sex (male) 0.34 1.588 0.614 4.107
High FL histological grade 0.202 0.502 0.174 1.448
Diffuse FL architectural pattern 0.105 0.25 0.047 1.338
B-symptoms 0.045 0.32 0.105 0.977
ECOG≥2 0.198 0.45 0.133 1.517
Bulky disease (≥10cm) 0.654 0.75 0.213 2.637
Ann Arbor Stage IV 0.207 1.852 0.711 4.826
Bone marrow involvement 0.251 1.75 0.673 4.552
High serum LDH (≥450 IU/L) 0.017 0.28 0.098 0.8
High serum β2M (≥3mg/L) 0.932 1.045 0.383 2.853
FLIPI 0.5 0.819 0.459 1.462
Variable P value Odds Ratio
95% C.I. for OR
Lower Upper
Age >60 y. 0.085 2.1 0.902 4.889
Sex (male) 0.727 1.16 0.505 2.662
High histological grade 0.194 1.971 0.708 5.483
Diffuse architectural pattern 0.999 0 0 -
B-symptoms 0.018 5.222 1.328 20.533
ECOG≥2 0.061 3.339 0.944 11.803
Bulky disease (≥10cm) 0.036 0.187 0.039 0.898
Ann Arbor Stage IV 0.242 1.69 0.702 4.07
Bone marrow involvement 0.357 1.504 0.631 3.582
High serum LDH (≥450 IU/L) 0.057 2.92 0.967 8.816
High serum β2M (≥3mg/L) 0.002 4.327 1.675 11.182
High risk FLIPI 0.005 4.144 1.527 11.245
Table 4.2. Correlation between High BTLA Total and the clinico-
pathological features at FL diagnosis.
Table 4.3. Correlation between High TNFRSF14 Total and the 
clinicopathological features at FL diagnosis.
The analysis consisted on binary logistic regression between BTLA 
Total and the different clinicopathological characteristics. High 
BTLA Total was defined as a percentage >8.58%, and low as 
<8.58%. In the logistic regression analysis "low" was considered as 
the reference.
The analysis consisted on binary logistic regression between 
TNFRSF14 Total and the different clinicopathological characteris-
tics. High TNFRSF14 Total was defined as a percentage >34.75%, 
and low as <34.75%. In the logistic regression analysis "low" was 
considered as the reference.
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undergo Ig SHM.29   In the light zone there is high quantity of 
naïve B lymphocytes and follicular dendritic cells, there the 
higher-affinity B cells (centrocytes) are positively selected 
thanks to the function of the follicular T helper cells (TFH). 
TFH cells drive the higher-affinity B cells proliferation and 
differentiation into the plasma cells.30   TFH cells are charac-
terized by a gene expression signature distinct from that of 
other T-cell subsets,31 and they can be identified by an array 
of markers including CXCR5, CXCL13, PD-1 (PDCD1), 
ICOS, SAP, CD200, BCL6, IL21 and MAF.32   BTLA was also 
identified among the genes specifically expressed in TFH 
cells.31   BTLA is a lymphoid receptor that inhibits lympho-
cyte activation and proliferation on interaction with its 
ligand, TNFRSF14.33   BTLA suppresses IL21 production 
from TFH cells and subsequent humoral immune responses.34 
BTLA is widely express in reactive lymph nodes, except in 
GC B cells.33   Among normal B cells, the highest BTLA 
expression is found in naïve B cells (CD20+, IgD+/CD38-).33 
In our study the expression in reactive tonsils confirmed 
those finding, BTLA was positive in the GCs with colocaliza-
tion with PD-1+TFH cells, the B lymphocytes of the mantle 
zones were also positive and in the interfollicular regions 
BTLA-positive cells were identified with a pattern similar to 
PD-1.   In FL we found that high BTLA expression in the fol-
licular region was associated with an improved OS.   These 
findings are like those that we had previously reported with 
PD-1 in FL, focusing on the follicular region.3   In addition, 
we found that the presence of a BTLA-positive mantle zone, 
which also stained with IgD, associated with good prognosis 
in FL.   Interestingly, chronic lymphocytic lymphoma also 
expresses BTLA33 and it is derived from CD5+B lympho-
cytes (B1 cells).   We found that BTLA expression in T-cells 
correlated with PD-1 and FOXP3, two markers associated 
with good prognosis in FL.1,3   Functional studies have con-
firmed the enrichment of TFH cells in the FL microenviron-
ment, which display a specific activation profile characterized 
by the expression of IL-4 that could sustain FL pathogene-
sis.35   Therefore, TFH cells seem to be necessary for the 
pathogenesis of FL and associates with good clinical evolu-
tion.   Importantly, as also seen with the PD-1 marker,3 
transformation to DLBCL is associated with a marked reduc-
tion of BTLA expression.
TNFRSF14 is the nexus in several signaling pathways 
and it plays important roles in the immune system, such as 
T-cell costimulation, regulation of dendritic cell (DC) 
homeostasis, autoimmune-mediated inflammatory responses, 
as well as host defense against pathogens.36   TNFSF14 
serves as a bimolecular switch to regulate the host immune 
response depending on which ligand it engages because 
TNFRSF14 functions as both a receptor with signal-transduc-
ing functions and as a ligand eliciting signaling.   As a recep-
tor, TNFRSF14 leads to the activation of NFkB, RELA, AP-1 
and AKT pathways that enhances cell proliferation, cytokine 
production and survival of TNFRSF14-expressing cells.36,37 
Antigen presenting cells (APCs, i.e. dendritic cells, macro-
phages and B cells) can express TNFRSF14.   As a ligand of 
BTLA on T cells will induce ITIM phosphorylation, recruit-
ment of SHP-1 and SHP-2 that will downregulate the TCR 
signaling pathway resulting in reduced cellular activation, 
proliferation, and cytokine production.36   Therefore, can 
inhibit the function of CD8+cytotoxic T cells and CD4+T 
helper cells, including TFH cells.34,38   In our study the 
expression of TNFRSF14 had a pattern of APCs including 
dendritic cells-macrophages and B-cells (centroblasts).   We 
found that a high expression correlated with poor prognosis 
in FL and with transformation to DLBCL.   In addition, 
GSEA analysis found an enrichment towards the “dead and 
high TNFRSF14 phenotype” of the NF-kB pathway.   Of 
note, the NF-kB pathway is related to the pathobiology and 
chemoresistance in FL and tFL.39   It has been reported that 
deletions of 1p36 and TNFRSF14 mutations are associated 
with worse prognosis of FL, but in that publication the 
authors did not analyze the protein expression of TNFRSF1440 
and, unfortunately, in our study we have not analyzed the 
mutational status.   TNFRSF14 receptor gene is among the 
most frequently mutated genes in germinal center lympho-
mas and loss of TNFRSF14 leads to cell autonomous activa-
tion of B cell proliferation and drives the development of GC 
lymphomas in vivo.41   TNFRSF14 deficient lymphoma B 
cells also induce a tumor supportive microenvironment 
Variable P value Hazard Ratio
95% C.I. for HR
Lower Upper
OS
High BTLA Total 0.143 0.563 0.261 1.214
High TNFRSF14 Total 0.001 3.605 1.699 7.647
High FLIPI 0.042 2.079 1.026 4.214
PFS
High BTLA Total 0.547 1.196 0.669 2.138
High TNFRSF14 Total 0.000144 3.118 1.735 5.604
High FLIPI 0.182 1.501 0.827 2.726
Table 5. Multivariate analysis between BTLA Total, TNFRSF14 
Total and FLIPI.
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Fig 6. Gene expression analysis of TNFRSF14 in FL.
At RNA level, high TNFRSF14 associated with worse OS using the LLMPP FL GSE16131 series. The GSEA 
plot showed an enrichment of the NFkB pathway towards the FL “dead - high TNFRSF14 phenotype”. 
Protein-protein interaction analysis of the TNFRSF14-NFkB pathway with molecular actions were as follows: 
green (activation), red (inhibition), blue (binding), pink (posttranslational modification).
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marked by exacerbated lymphoid stroma activation and 
increased recruitment of T follicular helper (TFH) cells in a 
FL mice model.41   These changes result from the disruption 
of inhibitory cell-cell interactions between the TNFRSF14 
and BTLA receptors.41   In our project the expression of 
TNFRSF14 was independent of the other components of the 
microenvironment that  we had analyzed: foll icular 
TNFRSF14 did not correlate with follicular PD-1 or follicu-
lar FOXP3.   Total TNFRSF14 did not correlate with total 
FOXP3 as well.   Total TNFRSF14 and total BTLA didn’t 
correlate either as continuous or as ordinal variable.   In a 
similar way, a mutual exclusive pattern of TNFRSF14 and 
BTLA expression in human FL samples was also described 
by Michael Boice et al.41   TNFRSF14 is considered as a 
tumor suppressor gene but this is when we focus on the effect 
on BTLA receptor that delivers inhibitory signals.   On the 
other hand, TNFRSF14, which is bidirectional, can also 
deliver stimulatory signals and therefore could be considered 
as having a tumor promoting function (Figure 7).38,42-44   The 
relationship with deletion, mutation and protein expression 
remains to be solved in future.
In summary, we found that high BTLA expression is 
associated with good prognosis, high TNFRSF14 expression 
with a bad prognosis in FL including a higher risk of trans-
formation, and that tFL expresses low BTLA but high 
TNFRSF14.   These observations suggest that the co-stimula-
tory and co-inhibitory BTLA-TNFRSF14 pathway plays a 
relevant role in the pathogenesis of FL.
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